PetMed Express Inc. (PETS) CEO Menderes Akdag Sells 6,274 Shares of Stock
PetMed Express Inc. (NASDAQ:PETS) CEO Menderes Akdag sold 6,274 shares of the company’s stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $22.25, for a total value of $139,596.50. Following the sale, the chief executive officer now directly owns 550,000 shares of the company’s stock, valued at $12,237,500. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Menderes Akdag also recently made the following trade(s):
- On Monday, November 14th, Menderes Akdag sold 40,000 shares of PetMed Express stock. The shares were sold at an average price of $21.63, for a total value of $865,200.00.
- On Monday, October 10th, Menderes Akdag sold 10,000 shares of PetMed Express stock. The shares were sold at an average price of $21.00, for a total value of $210,000.00.
- On Thursday, September 22nd, Menderes Akdag sold 10,000 shares of PetMed Express stock. The shares were sold at an average price of $20.75, for a total value of $207,500.00.
PetMed Express Inc. (NASDAQ:PETS) opened at 22.01 on Wednesday. The firm has a market cap of $445.77 million, a PE ratio of 20.57 and a beta of 1.11. PetMed Express Inc. has a 52-week low of $15.73 and a 52-week high of $22.37. The firm’s 50-day moving average price is $20.66 and its 200 day moving average price is $19.92.
PetMed Express (NASDAQ:PETS) last released its earnings results on Monday, October 24th. The company reported $0.24 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by $0.02. PetMed Express had a net margin of 9.10% and a return on equity of 25.77%. The business had revenue of $60.80 million for the quarter, compared to the consensus estimate of $58.47 million. During the same period in the prior year, the business posted $0.22 EPS. PetMed Express’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities analysts anticipate that PetMed Express Inc. will post $1.09 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, November 18th. Investors of record on Monday, November 7th were issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 3.45%. The ex-dividend date of this dividend was Thursday, November 3rd. PetMed Express’s dividend payout ratio is currently 71.03%.
ILLEGAL ACTIVITY NOTICE: This article was published by Financial Market News and is owned by of Financial Market News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at http://www.financial-market-news.com/petmed-express-inc-pets-ceo-menderes-akdag-sells-6274-shares-of-stock/1210272/.
Several institutional investors have recently added to or reduced their stakes in PETS. NEXT Financial Group Inc raised its position in PetMed Express by 167.2% in the second quarter. NEXT Financial Group Inc now owns 5,354 shares of the company’s stock valued at $100,000 after buying an additional 3,350 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in PetMed Express by 101.2% in the second quarter. BNP Paribas Arbitrage SA now owns 6,206 shares of the company’s stock valued at $116,000 after buying an additional 3,121 shares in the last quarter. Royal Bank of Canada raised its position in PetMed Express by 19.6% in the second quarter. Royal Bank of Canada now owns 6,423 shares of the company’s stock valued at $120,000 after buying an additional 1,053 shares in the last quarter. Cutler Group LP raised its position in PetMed Express by 832.0% in the second quarter. Cutler Group LP now owns 7,064 shares of the company’s stock valued at $132,000 after buying an additional 8,029 shares in the last quarter. Finally, Bank of Montreal Can acquired a new position in PetMed Express during the second quarter valued at approximately $143,000. 73.97% of the stock is currently owned by institutional investors.
PETS has been the subject of several analyst reports. Zacks Investment Research downgraded PetMed Express from a “buy” rating to a “hold” rating in a research note on Tuesday, September 27th. Credit Suisse Group AG reaffirmed a “sell” rating and set a $13.00 price objective on shares of PetMed Express in a research note on Tuesday, August 16th.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.